Huang Hongpeng, Wei Xuetao
Department of Bioactivity, SinoCellTech Ltd., Beijing 100176, China.
Department of Toxicology, School of Public Health, Peking University; Peking China.
Rheumatol Immunol Res. 2025 Jan 9;5(4):209-216. doi: 10.1515/rir-2024-0029. eCollection 2024 Dec.
Autoimmune diseases arise from immune system dysfunction that immune cells mistakenly attack the body's own tissues, resulting in systemic disorders or localized lesions such as systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Autoreactive B cells play a critical role in the pathogenesis of many autoimmune diseases and B cell depletion using anti-CD20 monoclonal antibody (mAb) has been shown to effectively mitigate disease progression in both preclinical and clinical studies. Recently, bispecific antibody (bsAb) targeting CD20/CD3 have demonstrated substantial clinical benefits in the treatment of various hematologic malignancies. Given their similar B cell cytotoxic mechanism, CD20/CD3 bsAb therapy may offer significant improvements in the management of many autoimmune diseases, providing a novel therapeutic option for patients. This concise review aims to summarize recent findings on CD20/CD3 bsAbs and discuss their potential in treating autoimmune diseases.
自身免疫性疾病源于免疫系统功能障碍，即免疫细胞错误地攻击身体自身组织，导致系统性疾病或局部病变，如系统性红斑狼疮（SLE）和类风湿性关节炎（RA）。自身反应性B细胞在许多自身免疫性疾病的发病机制中起关键作用，并且在临床前和临床研究中均已表明，使用抗CD20单克隆抗体（mAb）耗竭B细胞可有效缓解疾病进展。最近，靶向CD20/CD3的双特异性抗体（bsAb）在治疗各种血液系统恶性肿瘤方面已显示出显著的临床益处。鉴于其相似的B细胞细胞毒性机制，CD20/CD3 bsAb疗法可能在许多自身免疫性疾病的管理中带来显著改善，为患者提供一种新的治疗选择。这篇简明综述旨在总结关于CD20/CD3 bsAb的最新研究结果，并讨论其在治疗自身免疫性疾病方面的潜力。
